Daniel Spiegelman has industry knowledge and US corporate governance, compliance and financial management experience. He has held numerous executive and board roles, including as audit and risk committee chair, with several US public and private companies.
Mr Spiegelman has experience in the biotechnology industry who has provided strategic financial management, and has worked in a number of life science companies during his career.